NCT07770932 Deep Subgluteal Block vs PENG Combined With LFCN Block for Analgesia After Hip Arthroplasty
| NCT ID | NCT07770932 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medipol University |
| Condition | Postoperative Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-08-01 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-08-01 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized, prospective study aims to compare the clinical efficacy of ultrasound-guided Deep Subgluteal Block (DSGB) versus Pericapsular Nerve Group (PENG) block combined with Lateral Femoral Cutaneous Nerve (LFCN) block for postoperative analgesia management in patients undergoing hip arthroplasty. A total of 60 patients scheduled for hip arthroplasty under general anesthesia will be randomly allocated into two equal groups of 30: Group DSG and Group PENG+LFCN. Total local anesthetic volume (30 mL) and active drug dose (75 mg bupivacaine) will be standardized across both groups to ensure rigorous blinding and high methodological quality. The primary outcome of the study is to compare total postoperative opioid (fentanyl) consumption within the first 24 hours. Secondary outcomes include postoperative pain scores evaluated via the Numerical Rating Scale (NRS) at rest and during movement, the presence and degree of quadriceps motor block, and opioid-related adverse effects (e.g., nausea, vomiting, pruritus).
Eligibility Criteria
Inclusion Criteria: * Patients scheduled for elective total or partial hip arthroplasty under general anesthesia * American Society of Anesthesiologists (ASA) physical status I-III * Aged between 18 and 80 years * Able to understand the study procedures, give voluntary written informed consent, and operate a patient-controlled analgesia (PCA) device Exclusion Criteria: * Patient refusal or inability to provide informed consent * Pre-existing peripheral neuropathy, cognitive impairment, or psychiatric disorders * History of significant severe renal or hepatic failure * Allergy or hypersensitivity to amide-type local anesthetics or opioids * Infection, severe anatomic distortion, or previous surgery at the proposed block injection sites * History of substance abuse or chronic opioid use (defined as daily opioid use for \> 3 months prior to surgery)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07770932 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Postoperative Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07770932 currently recruiting?
Yes, NCT07770932 is actively recruiting participants. Contact the research team at yoatalay@medipol.edu.tr for enrollment information.
Where is the NCT07770932 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07770932 clinical trial?
NCT07770932 is sponsored by Medipol University. The trial plans to enroll 60 participants.